Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRI102
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Administration
- Oral
01
Overview
TRI102 is an investigational pharmaceutical drug currently in Phase 3 clinical trials for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12. The drug is administered once daily. The Phase 3 study is designed as a randomized, double-blind, placebo-controlled, parallel-group, multicenter, laboratory classroom study to evaluate its effectiveness.
02
Targets
DNATYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on TRI102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRI102.